Early chemotherapy discontinuation (>21 days before last pembrolizumab) in responders with ≥24-week clinical benefit showed ...
ERAS-0015 Phase 1 data, valuation gap, Merck deal, funding, and key risks like patents. Click for more on ERAS stock.
Is your child up to date with required SC vaccinations? Here's what's new for the upcoming school year.
Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head ...
Learn more about whether ADMA Biologics, Inc. or CareDx, Inc. is a better investment based on AAII's A+ Investor grades, ...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated ...
HKSH Proton Therapy Centre has demonstrated strong research depth on the international academic stage, injecting powerful momentum into precision cancer treatment for Hong Kong and the Greater Bay ...
Daily Maverick on MSNOpinion
Lenacapavir offers extraordinary promise but communication will decide its impact
A groundbreaking HIV prevention injection will only achieve its full impact if scientific advances are matched by clear, ...
HKSH's first-in-Asia comparative study found hypofractionated proton therapy prevented breast cancer recurrence with a 100 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results